LTR Pharma (ASX:LTP) Common Stock: A$44.11 Mil (As of Dec. 2025)


ASX:LTP LTR Pharma Ltd ASX:LTP
15 GF Score
Price A$0.58
View Full Analysis

What is LTR Pharma Common Stock?

LTR Pharma ASX:LTP +3.57% 15 Common Stock is A$44.11 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100.

LTR Pharma's quarterly common stock stayed the same from Dec. 2024 (A$44.11 Mil) to Jun. 2025 (A$44.11 Mil) and stayed the same from Jun. 2025 (A$44.11 Mil) to Dec. 2025 (A$44.11 Mil).

LTR Pharma's annual common stock declined from Jun. 2023 (A$10.78 Mil) to Jun. 2024 (A$10.74 Mil) but then increased from Jun. 2024 (A$10.74 Mil) to Jun. 2025 (A$44.11 Mil).

LTR Pharma Common Stock Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Common Stock Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Common Stock
0.00 2.79 10.78 10.74 44.11

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial 10.74 10.74 44.11 44.11 44.11
ASX:LTP
15GF Score
LTR Pharma Ltd ASX:LTP
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$44.11 Mil mean?
LTR Pharma (ASX:LTP) has a Common Stock of A$44.11 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on LTR Pharma and its competitors.
Is LTR Pharma's Common Stock too high?
LTR Pharma's current Common Stock is A$44.11 Mil. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Common Stock compare to VRTX and REGN?
LTR Pharma's Common Stock of A$44.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on LTR Pharma and its competitors. LTR Pharma's current Common Stock is A$44.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Common Stock of A$44.11 Mil. The current Common Stock is A$44.11 Mil. LTR Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Common Stock is A$44.11 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score

Get the complete analysis for ASX:LTP

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.58
Price